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An  effective  HIV-1  vaccine,  microbicide,   
or other pre- or post-exposure prophylactic 
must interdict virus at or near the moment of 
mucosal transmission or in the early period 
preceding the establishment of viral latency 
and disseminated infection (1–4). In humans, 
it has been difficult to study these earliest vi-
ral host events in vivo (2, 5–13), and in tissue 
explant cultures or in Indian rhesus macaques 
the HIV-1 or simian immunodeficiency vi-
rus (SIV) inocula have typically been high to 
achieve uniform infection of controls or to 
visualize  infection  events  in  situ  (14–20), 
thus prompting concerns about the physio-
logical relevance of the model systems (21–24). 
Further complicating the analysis of early in-
fection events in vivo is the viral “eclipse” 
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We recently developed a novel strategy to identify transmitted HIV-1 genomes in acutely 
infected humans using single-genome amplification and a model of random virus evolution. 
Here, we used this approach to determine the molecular features of simian immunodefi-
ciency virus (SIV) transmission in 18 experimentally infected Indian rhesus macaques. 
Animals were inoculated intrarectally (i.r.) or intravenously (i.v.) with stocks of SIVmac251 
or SIVsmE660 that exhibited sequence diversity typical of early-chronic HIV-1 infection. 
987 full-length SIV env sequences (median of 48 per animal) were determined from plasma 
virion RNA 1–5 wk after infection. i.r. inoculation was followed by productive infection by 
one or a few viruses (median 1; range 1–5) that diversified randomly with near starlike 
phylogeny and a Poisson distribution of mutations. Consensus viral sequences from ramp-up 
and peak viremia were identical to viruses found in the inocula or differed from them by 
only one or a few nucleotides, providing direct evidence that early plasma viral sequences 
coalesce to transmitted/founder viruses. i.v. infection was >2,000-fold more efficient than 
i.r. infection, and viruses transmitted by either route represented the full genetic spectra of 
the inocula. These findings identify key similarities in mucosal transmission and early 
diversification between SIV and HIV-1, and thus validate the SIV–macaque mucosal infec-
tion model for HIV-1 vaccine and microbicide research.
© 2009 Keele et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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RESULTS
Inoculation regimen and infection kinetics
18 animals received weekly atraumatic i.r. inoculations of 
cell-free SIV as part of a previous study of adaptive immune 
responses after mucosal virus exposure (41). The virus inoc-
ula were uncloned SIVmac251 or SIVsmE660 strains com-
prised of virus “swarms” with env diversity comparable to 
what is observed in humans 1–2 yr after infection by HIV-1 
(42). 9 animals, divided into groups of 3, received log dilu-
tions of 6 × 107, 6 × 106, or 6 × 105 vRNA copies of 
SIVsmE660 (Fig. 1, left). Nine other animals, divided into 
groups of three, received identical dilutions of SIVmac251 
(Fig. 1, right). Virus was administered weekly for 6 wk, fol-
lowed by a 3-wk observation period and a 2-mo rest period 
to ensure that none of the animals experienced delayed sero-
conversion. Animals were phlebotomized weekly during the 
inoculation–observation  period.  Animals  that  did  not  be-
come productively infected after the first inoculation–obser-
vation–rest cycle underwent a second 6-wk course of i.r. 
inoculations at the same virus dose level, followed by a 3-wk 
observation period and a 2-mo rest period. Animals that still 
did not become infected underwent a third 6-wk course of 
i.r. inoculations at the maximum virus dose level (6 × 107 
vRNA copies), followed by observation and rest periods. 
One animal, AV66, received SIVsmE660 for the initial two 
i.r. inoculation cycles and was then crossed over to receive 
SIVmac251 for the third i.r. inoculation cycle (Fig. 1, bottom 
left). 5 animals that did not become infected after the 18 i.r. 
inoculations were given a single i.v. inoculation of 2 × 105 
vRNA copies. All animals became infected.
The kinetics of virus infection and replication, and the 
time points of plasma virus sampling for env sequence analy-
sis, are illustrated (Fig. 1). There was no significant difference 
in the overall infection rate between macaques inoculated i.r. 
with SIVsmE660 (6 of 8 animals) versus SIVmac251 (7 of 10 
animals). Because of this similarity, and the relatively small 
number of animals in the study (n = 18), the 6 animals in 
each virus dose group were combined for purposes of statisti-
cal analysis. We found a statistically significant virus dose–
infection trend to i.r. infection, with 6 of 6 animals receiving 
the highest dose of SIV becoming infected in the first 8 wk 
inoculation–observation regimen, 4 of 6 animals receiving 
the intermediate dose becoming infected in the same period, 
and 1 of 6 animals receiving the lowest dose becoming in-
fected in the same period (P = 0.005 by 3 × 2 Fisher’s exact 
test). Two animals, AV66 and AH4X, did not become in-
fected after 12 weekly i.r. inoculations at the lowest dose of 
virus (6 × 105 vRNA copies), but did become infected after 
1–4 i.r. inoculations at the highest virus dose (6 × 107 vRNA 
copies). 5 animals, CP37, CR54, AV74, CG71, and CG5G, 
did not become infected even after 18 weekly i.r. inocula-
tions, but each became infected after a single i.v. inoculation. 
For both SIVsmE660- and SIVmac251-infected animals, the 
kinetics  of  plasma  viral  load  increase  were  quite  similar, 
reaching peak viremia within 1 wk of the last negative sample 
in three animals and within 2 wk in 15 others. Peak viral 
period during which virus replicates in mucosal and lo-
coregional lymphoreticular tissues but is not yet detectable 
in the circulating plasma (25). In SIV-infected macaques, 
the eclipse period is generally 4–7 d in duration, and in 
HIV-1–infected humans, it is 7–21 d (5, 18, 25–27).
Previously, we observed that in the early stages of HIV-1 
infection preceding antibody seroconversion (eclipse phase 
and Fiebig stages I and II [25]), virus diversification follows 
a pattern of random evolution with an almost starlike phy-
logeny and a Poisson distribution of nucleotide substitu-
tions (5). We thus hypothesized that the genetic identity 
of transmitted or early founder viruses could be inferred 
unambiguously by phylogenetic analysis of discrete low-
diversity viral lineages that emanate from them. This hypoth-
esis was supported by an analysis of 3,449 full-length env 
genes from 102 human subjects with acute HIV-1 subtype 
B infection, where we found that (a) acute viral sequences 
sampled  before  the  development  of  measurable  adaptive 
immune responses conformed to a pattern of random virus 
evolution; (b) viral sequence diversity resulted in model 
estimates  of  time  to  a  most  recent  common  ancestor 
(MRCA) that was consistent with clinical histories and 
Fiebig stage classifications; and (c) in most subjects (78 of 
102) there was evidence of productive infection by only a 
single virus, whereas in 24 other subjects infection resulted 
from transmission of at least 2 to 5 viruses, each recogniz-
able as a discrete virus lineage (5). These findings have since 
been corroborated in seven additional patient cohorts in-
fected by HIV-1 subtypes A, B, C, or D (28–35). A key 
innovation common to these studies was the use of singe-
genome  amplification  (SGA)  of  plasma  viral  RNA,  fol-
lowed by direct amplicon sequencing to characterize the 
virus quasispecies (5, 35–39). This method provides pro-
portional representation of plasma viral RNA (vRNA) and 
precludes Taq polymerase-induced template switching (re-
combination), Taq polymerase-associated nucleotide sub-
stitutions in finished sequences, template resampling, and 
cloning bias (5, 35, 37, 38, 40).
In this study, we sought to directly test our strategy for 
identifying transmitted/founder viruses in the Indian rhe-
sus macaque SIV infection model where we could define 
essential experimental parameters, including the route of 
SIV infection, genetic composition of the inoculum, and 
the duration between virus inoculation and sampling of 
plasma vRNA. The primary study objectives were two-
fold: first, to determine if, as our hypothesis and model 
predict, plasma SIV sequences sampled at or near peak   
viremia coalesce to sequences of viruses responsible for 
transmission and productive clinical infection weeks ear-
lier; and second, to determine how closely a low-dose 
SIV rectal transmission model in Indian rhesus macaques 
recapitulates features of human infection by HIV-1, in-
cluding the extent of the mucosal barrier to virus transmis-
sion, the number of transmitted/founder viruses leading to 
productive infection, and the molecular patterns of early 
virus diversification.JEM VOL. 206, May 11, 2009 
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Figure 1.  Viral kinetics after i.r. or i.v. infection. Groups of three animals received i.r. inoculations of SIVsmE660 or SIVmac251 in dosages indicated 
at weeks 0, 1, 2, 3, 4, and 5 (underlined) or by the i.v. route at week 0 (only) of the fourth cycle. Plasma was sampled at ramp-up (green symbols) or at 
peak (blue symbols) viremia for env sequence analysis. Numbers of transmitted/founder viruses found to be responsible for productive infection are indi-
cated in parenthesis. Plasma viral load determinations were previously reported (41).1120 LOW-DOSE MUCOSAL INFECTION BY SIV | Keele et al.
an almost starlike phylogeny (Fig. 2, A and B). Five other 
CP1W env sequences (RU.I3, RU.4B7, PK.I6, PK.4A29, 
and PK.I10) differed from the consensus by 3–7 nt, but these 
were notable for APOBEC-related G-to-A hypermutation 
(Fig. 2, A and B). Ramp-up sequences sampled 1 wk after 
infection, and peak viremia samples obtained 2 wk after 
infection, each coalesced to the same consensus sequence, 
which was identical to sequences in the inoculum. Thus, a 
single virus established productive clinical infection in CP1W, 
and it could be traced back from peak viremia through the 
eclipse phase of infection to the moment of transmission and 
into the inoculum.
Single, low-diversity viral lineages with starlike phylog-
eny and Poisson distributed substitutions were also found in 
i.r.-infected  animals  PBE  (Fig.  3  A),  CG87  (Fig.  4  A), 
AV66,  CR2A,  and  CR53  (Table  I).  In  each  animal,  se-
quences from ramp-up and peak viremia coalesced to single 
consensus sequences representing transmitted/founder viruses. 
In two of these animals (PBE and CR2A), the transmitted/
founder viruses differed from sequences identified in the 
inoculum  by  only  2  nt.  In  another  i.r.-infected  animal 
(CP23), ramp-up and peak viremia samples were not avail-
able for analysis, so we instead analyzed samples taken 2 wk 
after peak viremia, corresponding to 4–5 wk after infection 
(Fig. 1). The phylogenetic tree of CP23 sequences was dis-
tinctly different from the phylogenies of sequences from all 
other animals (Fig. S2). The Highlighter plot revealed an 
extraordinary  concentration  of  unique  and  shared  muta-
tions confined to a short stretch of 19 nt in the gp41 coding 
region of env overlapping the nef gene (Fig. S2). Here,   
32 out of 37 sequences in the env reading frame, and 34 out of 
37 sequences in the nef reading frame, contained amino   
acid substitutions compared with the transmitted/founder 
sequence and the consensus of sequences present in the 
SIVsmE660 inoculum. The clustered mutations in the Env 
reading frame were contiguous with a 9-mer Env peptide 
(FHEAVQAVW) corresponding to a known Mamu-B*17–
restricted  CTL  epitope  (43).  Animal  CP23  was  Mamu-
B*17 positive. These findings thus indicated that monkey 
CP23  was  infected  by  a  single  virus,  but  that  this  virus 
evolved extremely rapidly, most likely as a consequence of 
CTL selection pressure, such that by 4–5 wk after infection, 
>85% of viral sequences were escape variants. Similar pat-
terns and kinetics of rapid CTL escape have been reported 
for SIV and HIV-1 (5, 30, 35, 44, 45).
Six other animals (CG7V, CP3C, CG7G, AK9F, CT76, 
and  AH4X)  were  infected  by  i.r.  virus  inoculations  but 
showed  substantially  greater  maximum  pairwise  diversity 
among their sequences (0.59–1.43%) than did the animals 
that were productively infected by only a single virus (0.07–
0.15%, excluding CP23). NJ trees and Highlighter plots of 
sequences from these six animals revealed two or more dis-
crete low-diversity env lineages, each representing a distinct 
transmitted/founder virus (Figs. 5, 6, and S4). Overall, there 
was a trend observed between the virus inoculum dose that 
each animal received and the number of transmitted viral 
loads ranged from 1.4 × 105 to 9.4 × 107 (median 8 × 106) 
and were not related to the infecting virus strain or route of 
infection. A correlation between peak viral load and numbers 
of transmitted viruses was observed for SIVsmE660-infected 
(Spearman correlation coefficient 0.71; P = 0.05) and SIV-
mac251-infected  (Spearman  correlation  coefficient  0.91;   
P = 0.005) macaques.
Virus diversity in SIV inoculum stocks
The extent of virus sequence diversity in the inoculum stocks of 
SIVsmE660 and SIVmac251 was determined by SGA-direct 
sequencing of full-length vRNA env genes, followed by pair-
wise sequence comparisons, neighbor-joining (NJ) phylogenetic 
tree construction, and Highlighter analysis (Fig. S1). Highlighter 
is a sequence analytical tool (www.HIV.lanl.gov) that displays 
the location and identity of nucleotide substitutions in a visu-
ally informative manner and allows tracing of common ancestry 
between sequences based on individual nucleotide polymor-
phisms. Maximum diversity among 42 SIVsmE660 env sequences 
was 1.8%, and among 61 SIVmac251 sequences, diversity was 
0.8%. NJ trees of both sequence sets revealed structure in the 
phylogenetic relationships among sequences typical of primary 
virus isolates. Highlighter plots reflected this structured diversity.
Virus diversity in SIV-infected macaques
A total of 987 full-length SIV env genes of plasma virions from 
18 animals (median of 48 per animal; range 23–137) were 
amplified and sequenced. 26 sequences (distributed among 12 
animals) showed evidence of overt APOBEC G-to-A hyper-
mutation (e.g., sequences RU.I3, RU.4B7, PK.I6, PK.4A29 
and PK.I10 in Fig. 2). These sequences were retained in phy-
logenetic tree constructions but were excluded from diversity 
measurements and model calculations. Among the remaining 
961 sequences, maximum env diversity in animals infected i.r. 
ranged from 0.07 to 1.43% (median = 0.33%). Maximum env 
diversity in animals infected intravenously ranged from 0.18 
to 1.54% (median = 0.81%), which is not different from viral 
diversity in i.r.-infected animals (P = 0.11 by Wilcoxon rank 
sum test). i.r.-infected animals had env sequence diversities 
that fell into two distinctive groups, which we showed subse-
quently to reflect productive infection by one virus (maxi-
mum env diversity of 0.07–0.15%, median = 0.15%) or more 
than  one  virus  (maximum  env  diversity  of  0.59–1.43%, 
median = 0.95%; P = 0.0003 by Student’s t test of a general-
ized linear model of maximum env diversity).
Sequence diversity in animal CP1W, which was infected 
by the i.r. route, is illustrated by a NJ tree comprised of 137 
env sequences from ramp-up (green ovals) and peak (blue 
ovals) viremia along with 61 sequences from the SIVmac251 
inoculum (black ovals; Fig. 2 A). 102 of 137 CP1W env  
sequences were identical to themselves and to 4 sequences 
(K11, K9, G2, and TB2L) in the inoculum. 22 other CP1W 
env sequences differed from this consensus CP1W env se-
quence by 1 nt, and 8 CP1W env sequences differed from the 
consensus by 2 nt. Most of these 30 sequences differed from 
the consensus by unique mutations, which is consistent with JEM VOL. 206, May 11, 2009 
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Figure 2.  Viral sequence analysis after intrarectal SIVmac251 infection of animal CP1W. (A) NJ tree of sequences from ramp-up (green symbols) 
or peak (blue symbols) viremia or from the inoculum (black symbols). (B) Highlighter alignment of all CP1W sequences compared with four identical  
sequences from the inoculum and to the transmitted/founder virus. Nucleotide polymorphisms are indicated by a colored tic mark (thymine in red, guanine  
in orange, adenine in green, and cytosine in blue). APOBEC-mediated G-to-A mutations are indicated by purple tics, and deletions are indicated by gray 
tics. (C) Poisson model of early viral diversity. Brown labels indicate sequences with three or more APOBEC-mediated G-to-A mutations compared  
with consensus.1122 LOW-DOSE MUCOSAL INFECTION BY SIV | Keele et al.
For example, animal CT76 (Fig. S4) became infected by the 
i.r. route by four transmitted/founder viruses, two of which 
were  represented  only  transiently  in  the  ramp-up  sample 
(variants 3 and 4). In CT76, the data can best be explained by 
variants 1 and 2 outgrowing variants 3 and 4, which were lost 
altogether  from  the  sampled  sequences  by  peak  viremia. 
Macaque CG7V (Fig. 5) is a second example of an animal 
infected i.r. by five viruses, two represented by predominant 
env sequence lineages and three by single sequences (variants 
3, 4, and 5). Macaque CP3C (Fig. 6) is a third example of an 
animal that was infected i.r. by at least three viruses, two of 
which were well represented and one that was represented by 
only a single ramp-up sequence (variant 3). We amplified an 
additional 220 env genes from ramp-up plasma viruses from 
this animal and identified just one additional member of this 
transmitted/founder lineage (unpublished data). Thus, this 
rare variant represented <1% (2/269 sequences) of the repli-
cating virus population. Notably, among the 269 sequences 
analyzed, we found no additional transmitted/founder virus 
lineages beyond the three depicted in Fig. 6. Animals CG7G 
and AK9F (Fig. S5) are two more examples of monkeys 
infected i.r. by multiple viruses, one or two of which were 
represented by lineages containing only single-sampled vari-
ants. Animals infected by the i.v. route were even more com-
plicated because of the greater number of transmitted viruses 
overall (Figs. 3 B, 4 B, 7, S3, and S5). Compounding the un-
equal representation of sequences resulting from differences 
in replication efficiencies was the effect of recombination be-
tween viruses of two or more transmitted lineages. This is 
best seen in animal CG7V (Fig. 5), where recombinant viruses 
outnumbered one of the two principal transmitted lineages 
by nearly 3 to 1, and the minor variants by 20 to 1. Recom-
bination was also observed in sequences from animals CG7G, 
CR54, CG71, and CG5G (Table I and Fig. S3).
Phylogenetic distribution of transmitted/founder viruses  
in the inocula
Sequences from all SIVmac251-infected animals and from 
the corresponding SIVmac251 inoculum are depicted in a 
single NJ tree (Fig. 7). Animals AV74, CG71, and CG5G 
were each inoculated by the i.v. route, and the >14 transmit-
ted/founder sequences that productively infected these ani-
mals are distributed widely throughout the tree. Several of 
these sequences differ from inoculum sequences by only 1 nt. 
Also represented in this NJ tree are sequences from seven ani-
mals infected by the i.r. route. Sequences from each of these 
animals are represented by one or more discrete low-diversity 
lineage  whose  consensus  either  matches  an  inoculum  se-
quence (CP1W) or differs by only 1 or 2 nt (CT76, CR2A, 
and AH4X). Again, these transmitted/founder virus lineages 
are distributed widely throughout the tree. A similar pattern 
of inoculum and transmitted/founder SIVsmE660 env se-
quences is shown in Fig. S5. These findings highlight the 
diversity of env sequences in the SIVsmE660 and SIVmac251 
inocula that are capable of mediating virus transmission and 
productive replication in macaques by i.v. or i.r. routes.
variants leading to productive clinical infection: among the 
12 animals receiving the two highest doses of virus in the 
initial inoculation-observation cycle, a minimum of 26 
viruses were transmitted to 10 animals. Among the six ani-
mals inoculated with the lowest dose of virus, one virus was 
transmitted to a single animal. However, this dose–response 
trend was not proportional across all dosage levels, and thus 
was  not  statistically  significant,  as  animals  receiving  the 
highest virus inoculum did not differ from animals receiving 
the intermediate virus inoculum in the numbers of viruses 
leading to productive clinical infection.
Five animals did not become infected by the i.r. route 
despite 18 weekly inoculations (Fig. 1). Each of these animals 
did, however, become productively infected after a single i.v. 
inoculation of virus (2 × 105 vRNA copies). This i.v. dose 
was 300-fold lower than the maximum single i.r. dose (6 × 107) 
that each of the five animals had received and 2,000-fold 
lower than the cumulative i.r. dose that each animal had 
received (Fig. 1 and Table I). Figs. 3 B and 4 B show NJ trees 
and Highlighter plots of env sequences from i.v.-infected ani-
mals CG71 and CP37. Even when animals were infected 
with multiple viruses, the progeny of transmitted/founder 
viruses could be identified with certainty in cases where two 
or more sequences were identical (e.g., CG71 env sequences 
corresponding to variants 1, 2, 6, 7 and 8 in Fig. 3 B), and 
with high likelihood if two or more sequences differed by 
only one or few nucleotides (e.g., CG71 env sequences cor-
responding to variants 3, 4, and 5 in Fig. 3 B). Identification 
of transmitted/founder viruses was less certain for individual 
sequences that were dispersed throughout the inoculum tree 
because such viruses could represent either transmitted vari-
ants (that replicated less efficiently) or unique recombinant 
viruses between two or more transmitted lineages. Thus, we 
made a conservative estimate that i.v. inoculation of animal 
CG71 resulted in productive infection by at least eight trans-
mitted viruses. We reached a similar conclusion for animal 
CP37 (Fig. 4 B), for which there was evidence of productive 
infection by at least nine viruses. These are minimal estimates 
because as the number of transmitted viruses increases, the 
likelihood of sampling at least one of its progeny becomes 
increasingly dependent on the total number of sequences 
analyzed. For the five animals infected by the i.v. route, the 
number  of  transmitted/founder  viruses  that  we  identified 
ranged from 1 to >9 with a median of 4 (Table I). Because 
each of these animals had not been infected by a cumulative 
i.r. dose of 3.7–4.3 × 108 vRNA equivalents, but had 
become infected by 2 × 105 vRNA equivalents given i.v., we 
could use these values together with the numbers of transmit-
ted/founder viruses in each animal to estimate the relative 
efficiency of virus transmission by i.v. versus i.r. routes. We 
thus determined that i.v. transmission was 2,000–20,000-fold 
more efficient than i.r. transmission (Table I).
Detection of transmitted variants with minor representation
In some animals, the representation of viral lineages corre-
sponding to transmitted/founder viruses was far from even. JEM VOL. 206, May 11, 2009 
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Figure 3.  Viral sequence diversity after i.r. or i.v. SIVmac251 infection. (A) NJ and Highlighter analyses of sequences from i.r.-infected animal PBE 
at ramp-up (green symbols) or peak (blue symbols) viremia compared with inoculum sequences (black symbols). (B) i.v.-infected animal CG71. Brown 
labels indicate sequences with three or more APOBEC-mediated G-to-A mutations compared with consensus.1124 LOW-DOSE MUCOSAL INFECTION BY SIV | Keele et al.
Figure 4.  Viral sequence diversity after i.r. or i.v. SIVsmE660 infection. (A) NJ and Highlighter analyses of sequences from i.r.-infected animal 
CG87 at ramp-up (green symbols) or peak (blue symbols) viremia compared with inoculum sequences (black symbols). (B) i.v.-infected animal CP37. Nine 
transmitted/founder variant lineages are indicated, although additional minor variants and recombinants are also evident (see text). Bracket indicates a 
single-nucleotide insertion.JEM VOL. 206, May 11, 2009 
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Model analysis of SIV diversification
We previously described a mathematical model of HIV-1 
replication and diversification in acute infection (5) using esti-
mated parameters of HIV-1 generation time, reproductive 
ratio, and RT error rate and assuming that the initial virus 
replicates exponentially, infecting R0 new cells at each gen-
eration and diversifying under a model of evolution that   
assumes no selection, no back mutations, and a constant   
mutation rate across positions and lineages. Here, we applied 
this model to an analysis of 987 SIV env sequences and asked 
if measured parameters of virus diversification were consis-
tent with the assumptions and predictions of this model. We 
examined data from all 18 animals. For those animals infected 
by more than one transmitted/founder virus, we selected a 
predominant lineage for analysis and excluded minor lineages 
and recombinant viruses. One animal (CP37) could not be 
analyzed for model conformation because it was infected by 
so many viruses that none formed a sufficiently predominant 
lineage (Fig. 4 B). A second animal (CP23) was included in 
the analysis, but with the caveat that sequences were obtained 
from a time point 2 wk after peak viremia, and 4–5 wk after 
infection, when rapid CTL selection is known to occur in 
Table I.  Characterization of SIV transmission by intrarectal or intravenous inoculation
Subject Initial 
dose
Cumulative 
dose  
before  
first + 
vRNA
Time 
to  
first + 
vRNA 
(wk)
Infection 
route
Peak 
viral 
load
No. of 
env 
seq.  
per 
animal
No. of 
identified  
transmitted 
variants
Percent 
max. 
env 
diver-
sity
APOBEC-
mediated 
G-to-A 
muta-
tions
No. of 
APOBEC-
mutated 
sequences
Intra-
host 
recom-
bination
Starlike 
phylo-
genya
Poisson 
distri- 
butiona,b
Rectal 
barrierc
SIVsmE660-infected animals
CG7V 6 × 107 1.2 × 108  2 i.r. 77,871,700 96 5 1.06 Yes 2 Yes Yes Yes
CP3C 6 × 107 1.2 × 108  2 i.r. 1,112,900 49 3 0.84 Yes 1 No Yes Yes
CG87 6 × 107 3.6 × 108 6 i.r. 479,543 56 1 0.15 No – N/A Yes Yes
CG7G 6 × 106 6.0 × 106 1 i.r. 7,084,600 43 5 1.21 Yes 1 Yes Yes Yes
AK9F 6 × 106 3.6 × 107 6 i.r. 140,795 35 4 1.43 No – No Yes Yes
CP37 6 × 106 4.3 × 108 18 i.v. 94,394,600 62 >9 1.54 N/Ad N/Ad N/Ad N/Ad N/Ad >19,350
CP23e 6 × 105 1.2 × 106 2 i.r. 74,000,000 37 1 0.33e Yes 1 N/A Noe Noe
CR54 6 × 105 3.7 × 108 18 i.v. 1,968,800 29 4 1.26 Yes 1 Yes Yes Yes 7,400
SIVmac251-infected animals
CP1W 6 × 107 6.0 × 107 1 i.r. 17,797,900 137 1 0.15 Yes 5 N/A Yes Yes
CT76 6 × 107 6.0 × 107 1 i.r. 18,233,200 50 4 0.66 Yes 1 No Yes Yes
PBE 6 × 107 3.0 × 108 5 i.r. 10,955,200 41 1 0.15 No – N/A Yes Yes
CR2A 6 × 106 1.2 × 107 2 i.r. 4,130,600 46 1 0.07 No – N/A Yes Yes
CR53 6 × 106 3.6 × 107 6 i.r. 6,341,200 30 1 0.15 Yes 1 N/A Yes Yes
AV74 6 × 106 4.3 × 108 18 i.v. 18,690,000 71 1 0.18 Yes 3 N/A Yes Yes 2,150
AH4X 6 × 105 2.5 × 108 16 i.r. 2,611,600 23 2 0.59 No – No Yes Yes
CG71 6 × 105 3.7 × 108 18 i.v. 8,857,400 67 >8 0.73 Yes 3 Yes Yes Yes >14,800
CG5G 6 × 105 3.7 × 108 18 i.v. 12,938,400 71 4 0.81 Yes 2 Yes Yes Yes 7,400
AV66 6 × 105 6.7 × 107 13 i.r. 4,858,300 44 1 0.07 Yes 1 N/A Yes Yes
aIf infected with more than one variant, the major lineages were examined for a starlike phylogeny and Poisson distribution of substitutions excluding APOBEC-mediated 
changes.
bAPOBEC-mutated sequences excluded.
cRectal barrier was calculated by dividing the cumulative i.r. dose by the i.v. dose multiplied by the number of transmitted viruses.
dNot applicable; too many variants to quantify.
eSampled 2 wk after peak viral load.
SIV-infected macaques (44, 45) and HIV-1–infected humans 
(5, 30, 35). For each animal, we obtained the frequency dis-
tribution of all intersequence Hamming distances (HDs; 
defined as the number of base positions at which two genomes 
differ) within a lineage and determined if it deviated from a 
Poisson model using a 2 goodness-of-fit test. We then deter-
mined whether or not the observed sequences evolved under 
a star phylogeny model (i.e., all evolving sequences are 
equally likely and all coalesce at the founder) in the expected 
time frame based on the known or estimated date of infec-
tion. Sequences from 16 of 17 animals exhibited an almost 
starlike phylogeny, the one exception being animal CP23 
(Table I). Sequences from only 5 of 17 animals exhibited a 
Poisson distribution of base substitutions. The other 12 animals 
had sequences that showed enrichment for G-to-A hyper-
mutation with APOBEC signatures (Table I). In 7 of these 12 
animals, the evidence for hypermutation was restricted to a 
single sequence, whereas in 5 others, G-to-A hypermutation 
was enriched across multiple sequences. When these APO-
BEC-associated mutations were excluded from the analysis, a 
good fit to the Poisson model was restored for sequences 
from all 12 animals (Table I). 10 animals had rare sequences 1126 LOW-DOSE MUCOSAL INFECTION BY SIV | Keele et al.
after peak viremia (5, 30, 35). Sequences from animals infected 
by more than one virus also violated model expectations for 
a Poisson distribution and starlike phylogeny of mutations, 
but did conform to the model when env sublineages were ana-
lyzed individually (Table I).
Table II summarizes model estimates of time to a MRCA 
sequence in each animal. For this analysis, we used Bayesian 
(46, 47) and Poisson-based (5) approaches (Supplemental   
materials and methods). Bayesian and Poisson estimates of a 
MRCA of sequences in most animals were consistent with the 
known or estimated days since infection. This is best seen in 
animal CP1W, where 137 sequences (69 from ramp-up and 68 
from peak viremia) were analyzed, and for which both the du-
ration of infection before plasma sampling and the env sequence 
of the transmitted virus were known with certainty. Here, we 
observed the Poisson model estimate of a MRCA for ramp-up 
sequences to be 6 d (confidence interval [CI] 1–10 d) and for 
peak viremia sequences to be 10 d (CI 5–15 d). Bayesian cal-
culations used sequence information from both time points to 
that exhibited shared mutations. For example, CG87 (Fig. 4 A) 
contained 3 of 56 sequences that shared one nucleotide poly-
morphism, 3 other sequences that shared a different poly-
morphism, and 3 additional sequences that shared 1 or 2 still 
different polymorphisms. Animal CT76 (Fig. S4) had 3 of   
50 sequences that shared a singe-nucleotide polymorphism. 
Based on the temporal appearance and patterns of these mu-
tations and a mathematical modeling estimate of the expected 
frequency of sequences having one or more shared mutations 
in a gene the size of env (5, 30), we could explain these rare 
sublineages as resulting from stochastic mutations generated 
shortly after transmission. In contrast, sequences from animal 
CP23 obtained 2 wk after peak viremia contained a far higher 
number of shared mutations than did sequences from any 
other animal. Most of these shared mutations were narrowly 
confined to a short stretch of 19 nt. Thus, CP23 sequences 
severely violated model predictions for random variation as a 
consequence of early selection, similar to findings we made 
in HIV-1–infected humans who were sampled within 2 wk 
Figure 5.  i.r. transmission of five viruses, followed by extensive recombination. NJ and Highlighter plots from animal CG7V at ramp-up (green 
symbols) or peak (blue symbols) viremia with recombinant sequences labeled in purple (#) and minor transmitted/founder viral variants 3, 4, and 5 in red 
(*). Brown labels indicate sequences with three or more APOBEC-mediated G-to-A mutations compared with consensus.JEM VOL. 206, May 11, 2009 
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sible for productive clinical infection could be identified by 
phylogenetic inference in acutely infected subjects (5). A 
key inference from this model and the supporting HIV-1 
sequence datasets (5, 28–35) is that between the time the 
first cell is infected in the mucosa or submucosa and the 
time peak viremia is reached 3–5 wk later (eclipse phase 
and Fiebig stages I and II), viruses diversify essentially ran-
domly with little or no evidence of biological selection. 
This is in contrast to the period immediately thereafter 
(Fiebig stages III-V), when evidence of strong CTL selec-
tion generally becomes apparent (5, 30, 35). Using pyro-
sequencing technologies that allow for a more extensive 
sampling of sequences, we have recently found evidence of 
CTL selection beginning as early as Fiebig stage II (unpub-
lished data). A second key inference from the model and 
HIV-1 datasets is that by analyzing env sequence diversity 
among 30–50 plasma viruses sampled near the time of peak 
viremia, sufficient sequence information is available to allow 
for an unambiguous phylogenetic inference of transmitted/
founder virus(es) weeks earlier. This conclusion is based on 
power calculations that provide 95% confidence limits for de-
tecting minor sequence variants and the empirical observation 
estimate a coalescent MRCA for the peak viremia sequences of 
12 d (CI 8–20 d). Thus, Poisson and Bayesian estimates con-
curred closely with each other and with the known duration of 
infection of the animal. Model estimates of time to a MRCA 
were not close to the known duration of infection for animal 
CP23, which was sampled 2 wk after peak viremia when there 
was evidence of strong selection for mutations. Selected muta-
tions are nonrandom and violate model assumptions. For CP23, 
the Bayesian estimate for a MRCA was 50 d (CI 28–84 d) 
and the Poisson estimate was 55 d (CI 47–62 d), exceeding the 
known duration of infection of 28–35 d. For three animals 
(CR2A, CG5G, and AV66), the Poisson estimates and CIs of 
days since a MRCA were less than the known or estimated 
duration of virus infection, possibly because of purifying selec-
tion, differences in virus replication parameters such as virus 
generation time, RT error frequency or R0 compared with 
model assumptions, or a sampling effect.
DISCUSSION
Previously, we developed a conceptual framework, mathe-
matical model, and empirical dataset of HIV-1 env sequences 
that together suggested transmitted/founder viruses respon-
Figure 6.  Unequal representation of transmitted viruses. Transmitted variants 1 and 2 in animal CP3C are well represented at ramp-up (green sym-
bols) and peak (blue symbols) viremia compared with a third transmitted variant (red asterisk) that is represented by only a single sequence at ramp-up. 
Inoculum sequences are indicated by black symbols.1128 LOW-DOSE MUCOSAL INFECTION BY SIV | Keele et al.
Figure 7.  Composite SIVmac251 tree from i.r.- and i.v.-infected animals. The NJ tree depicts numerous transmitted/founder virus lineages 
distributed throughout a diverse set of inoculum sequences (black symbols). Most i.r.- or i.v.-transmitted viruses are represented by discrete, low-diversity  
lineages. Animal designation, route of infection, and numbers of transmitted viruses are indicated.JEM VOL. 206, May 11, 2009 
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lation and plasma sampling for env sequence analysis, could 
be better defined (Fig. 1).
Fig.  2  illustrates  ramp-up  and  peak  viremia  plasma 
vRNA sequences in animal CP1W after a typical i.r. infec-
tion by SIVmac251 and demonstrates many of the salient 
features of the SGA-direct sequence analysis. After elimina-
tion of five sequences that contained APOBEC-related 
G-to-A hypermutations, the remaining 132 env sequences 
conformed to a star-like phylogeny and exhibited a Poisson 
that between transmission and peak viremia (Fiebig stage II), 
it is uncommon to find sequences that exhibit shared poly-
morphisms resulting from immune selection (5, 30); when 
this does occur, it is necessary to analyze sequential samples 
to distinguish transmitted/founder sequences from selected 
mutants. In this study, we tested our model assumptions and 
inferences  directly  in  the  SIV–macaque  infection  model 
where experimental conditions, including the composition 
of the virus inoculum and the interval between virus inocu-
Table II.  Model analysis of early SIV evolution in SIVsmE660- and SIVmac251-infected rhesus macaques
Subject Sample time  Infection 
route
 No. of 
sequences 
examined
Max. HD BEAST 
estimated 
days since 
MRCA  
(95% CI)
Poisson 
estimated 
days since 
MRCA  
(95% CI)
a SDb Goodness of 
fit p-valuec
SIVsmE660-infected animals  
CG7V Ramp-up i.r. 39 2 6 (3,8) 0.308 0.082 0.584
  Peak i.r. 23 4 12 (8,19) 13 (7,20) 0.762 0.190 0.840
CP3C Ramp-up i.r. 19 3 13 (6,20) 1.053 0.189 0.913
  Peak i.r. 10 3 17 (10,29) 11 (3,18) 1.000 0.220 0.815
CG87 Ramp-up i.r. 23 4 15 (8,22) 0.854 0.210 0.663
  Peak i.r. 33 4 20 (12,34) 23 (18,28) 1.311 0.156 0.220
CG7G Ramp-up i.r. 18 2 12 (6,17) 0.667 0.159 0.317
  Peak i.r. 17 3 16 (10,27) 13 (6,20) 0.750 0.209 0.865
AK9F Peak i.r. 19 4 12 (2,43) 14 (7,22) 0.807 0.216 0.886
CP37d – – – – – – – – –
CP23 2 wk after 
peak
i.r. 37 8 50 (28,84) 55 (47,62) 3.129 0.221 0.038
CR54 Peak i.v. 17 3 14 (2,52) 12 (5,20) 0.706 0.206 0.874
SIVmac251-infected animals  
CP1W Ramp-up i.r. 69 4 6 (1,10) 0.316 0.123 0.654
  Peak i.r. 68 4 12 (8,20) 10 (5,15) 0.552 0.143 0.906
CT76 Ramp-up i.r. 20 3 17 (10,24) 0.968 0.208 0.809
  Peak i.r. 22 3 16 (7,34) 7 (1,12) 0.455 0.153 0.701
PBE Ramp-up i.r. 17 2 6 (2,11) 0.353 0.139 0.646
  Peak i.r. 24 4 13 (8,21) 12 (7,17) 0.667 0.142 0.211
CR2A Ramp-up i.r. 19 3 2 (0,5) 0.105 0.077 0.750
  Peak i.r. 27 2 8 (7,14) 5 (2,9) 0.296 0.101 0.637
CR53 Peak i.r. 30 4 12 (3,58) 12 (6,18) 0.667 0.166 0.478
AV74 Ramp-up i.v. 35 3 5 (2,9) 0.284 0.103 0.703
  Peak i.v. 36 3 12 (8,20) 14 (8,20) 0.778 0.174 0.621
AH4X Peak i.r. 21 6 11 (2,80) 10 (4,16) 0.561 0.173 0.894
CG71 Ramp-up i.v. 22 2 7 (2,11) 0.364 0.124 0.617
  Peak i.v. 16 5 14 (8,25) 17 (8,27) 0.983 0.279 0.630
CG5G Ramp-up i.v. 24 4 6 (1,11) 0.333 0.137 0.655
  Peak i.v. 17 4 9 (7,14) 6 (2,11) 0.353 0.136 0.646
AV66 Ramp-up i.r. 20 2 5 (1,9) 0.300 0.115 0.657
  Peak i.r. 24 2 9 (7,28) 3 (0,6) 0.167 0.082 0.713
aMean of best fitting Poisson distribution defined by the free parameter .
bSD of  obtained by using jacknife.
cP < 0.05 indicates that sequences deviate significantly from a Poisson distribution.
dNot applicable; too many variants to identify major lineage.1130 LOW-DOSE MUCOSAL INFECTION BY SIV | Keele et al.
exceed rectal transmission efficiency by 2,000–20,000-fold. 
This finding is consistent with the demonstrably higher risk 
of HIV-1 transmission resulting from i.v. exposure to con-
taminated blood products than from sexual exposures in humans 
(4, 57, 58) and comparable findings in SIV-inoculated mon-
keys (26, 55, 56).
One peculiarity in the findings illustrated in Fig. 1 is the 
observation that while i.r. inoculation with the two higher 
viral doses resulted in greater numbers of transmitted viruses 
compared with the lowest dose, this relationship was not 
proportional across all three virus dose levels. For example, 
there were animals in the highest dose group (e.g., CP1W 
and CG87) that were infected by a single virus and other 
animals in the middle dose group (e.g., AK9F and CG7G) 
that were infected by four or five viruses. This observation 
in macaques has an interesting parallel in humans where 
two recent studies of mucosal HIV-1 infection revealed that 
transmission of multiple viruses did not follow an expected 
Poisson distribution of independent, low-frequency events 
(5, 31). In those studies, the proportion of individuals who 
acquired more than one HIV-1 variant was higher than 
could be plausibly explained by known rates of HIV-1 sex-
ual transmission (4, 57, 58). Moreover, the proportion of 
individuals who became infected by three or more viruses 
was disproportionately higher still. At present, there is no 
satisfactory biological explanation in humans or macaques 
for  the  observed  non-Poisson  distribution  of  infection 
events, although mucosal tears, ulceration, inflammation, or 
infection by multiply infected cells or virus aggregates are 
possibilities (31, 33).
Three features of SIV mucosal transmission that differ 
from HIV-1 mucosal transmission are a shorter eclipse pe-
riod for SIV, a higher frequency of G-to-A hypermutated 
SIV sequences, and a higher frequency of detection of minor 
transmitted SIV variants (identified as rare variant sequences 
in ramp-up or peak viremia samples). Although the design 
of this study, which included weekly i.r. inoculations of 
virus and weekly plasma sampling, was not intended to pro-
vide a precise estimate of the duration of the eclipse period, 
we could determine an upper boundary for the eclipse phase 
in animals CP1W, CT76, CG7G, and AV66. In each case, 
it was < 7 d. This is substantially shorter than the average 
eclipse phase of HIV-1 in humans of 10–14 d, and which 
may exceed 21 d (for review see [5]). Potential explanations 
for this difference include an 10-fold lower plasma and 
extracellular fluid volume in macaques into which virus can 
distribute, together with a higher exponential growth rate 
and  reproductive  ratio  for  SIV  compared  with  HIV-1 
(27, 59). A second difference between SIV and HIV-1 
mucosal transmission was a substantially higher frequency 
of detection of SIV sequences with APOBEC-related G-to-A 
hypermutation in the acute and early infection period. For 
example, SIV env sequences from 12 of 18 macaques ini-
tially did not conform to a Poisson model of random virus 
evolution  because  of  APOBEC  hypermutation,  whereas 
HIV-1 env sequences from only 13 of 81 humans (5) deviated 
distribution of nucleotide substitutions. At 7 d after infec-
tion, 59 of 67 (88%) sequences were identical, and at 14 d 
after infection, 51 of 65 (78%) sequences were identical. 
This degree of early SIV env sequence homogeneity fol-
lowed by a decline in sequence identity from 88% to 78% 
over a 7-d period is strikingly similar to findings made in 
humans acutely infected by HIV-1 and conforms closely to 
model  projections  previously  reported  (5).  Bayesian  and 
Poisson estimations of days from a MRCA were consistent 
with the known duration of infection in this animal (Table II), 
and an unambiguous transmitted/founder SIVmac251 se-
quence could be inferred from the consensus of sequences 
at ramp-up and peak viremia time points. The validity of 
this conclusion was confirmed by an analysis of the SIV-
mac251 inoculum (Fig. 2), where four env sequences were 
found that were identical to the transmitted/founder env se-
quence in animal CP1W. This result shows that a transmit-
ted SIV genome can be identified in an inoculum, and can 
then be traced across the rectal mucosa of the newly in-
fected host and through the period of massive virus expan-
sion in gut-associated and peripheral lymphoid tissues that 
leads ultimately to peak plasma viremia (2, 3, 19, 45, 48–52). 
Recent studies in human transmission pairs where identical 
HIV-1 env sequences were identified in donor and recipient 
plasma after sexual HIV-1 transmission corroborate these 
findings (28, 33).
Despite the identification of one or more transmitted/
founder env genes in all 18 animals studied, we note that the 
detection of such discrete, low-diversity SIV lineages (repre-
senting the progeny of transmitted/founder viruses) does not 
mean that these represented the only viruses transmitted across 
the mucosal epithelium. It is possible that additional viruses 
were transmitted across the mucosa, but went undetected be-
cause of limited sampling, stochastic infection events, abor-
tive infection, defective viruses, innate immune responses, 
unequal replication rates of competing virus lineages, or   
virus compartmentalization (26, 53–56). The same is true for 
HIV-1–infected humans where determinations of numbers 
of transmitted/founder viruses correspond to minimum esti-
mates (5). With these caveats in mind, we obtained mini-
mum estimates of the numbers of transmitted viruses leading 
to productive clinical infection in the 18 macaque monkeys 
infected by i.r. or i.v. routes. The results are depicted in Fig. 1 
and are summarized in Table I, where the cumulative virus 
dose administered to each animal before the first positive 
plasma vRNA result is also listed. The findings show that 
rectal inoculation of SIV led to productive infection by a 
minimum of 1–5 viruses (median = 1). Five animals did not 
become infected even after 18 rectal inoculations. Each of 
these animals did become infected after a single intravenous 
inoculation with a dose of virus 300-fold less than the highest 
individual i.r. dose. These animals were productively infected 
by a minimum of 1–9 viruses (median = 4). After accounting 
for differences in the cumulative i.r. virus exposure of these 
animals and the minimum estimates of the numbers of trans-
mitted viruses, i.v. transmission efficiency was calculated to JEM VOL. 206, May 11, 2009 
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from the model because of APOBEC hypermutation (P < 
0.0001;  Fisher’s  exact  test).  In  a  separate  study,  we  also 
found examples of excessive G-to-A hypermutation of SIV 
in mucosally infected animals in the acute infection period 
(60). Heterogeneity of vif sequences in the SIV inoculum 
and in the transmitted/founder viruses that arise from them, 
or a greater evolutionary mismatch between SIVsm (SIV-
mac) Vif proteins and the Indian rhesus macaque APOBEC, 
compared with SIVcpz (HIV-1) Vif proteins and human 
APOBEC (61), may contribute to these differences. A third 
difference we found between mucosal SIV and HIV-1 in-
fection was in the numbers of minor virus variants detected 
in ramp-up or peak viremia plasma samples. Rare virus 
variants were found in 5 of 13 mucosally infected macaques 
compared with 4 of 98 human subjects (5) (P = 0.001; Fish-
er’s exact test). This difference may be caused by the fact 
that macaques were inoculated i.r. with higher titers of 
virus having greater diversity in replicative potential (as a 
consequence of in vitro propagation) compared with virus 
that is transmitted sexually in humans (4, 58, 62, 63) or to 
later sampling of humans (5).
In summary, this study demonstrates that i.r. infection 
of rhesus macaques recapitulates at a biological and molec-
ular level many of the features of human HIV-1 mucosal 
transmission. When the SIV inoculum is sufficiently low, 
mucosal transmission is infrequent and dose related; higher 
SIV doses, like higher HIV-1 titers in humans (58, 62–64), 
are associated with higher transmission rates. The numbers 
of transmitted/founder viruses yielding productive clinical 
infection  in  mucosally  infected  humans  (generally  1–5; 
median = 1; [5, 28, 29, 31–35)]) and macaques (1–5; me-
dian = 1) were low, reflecting a substantial bottleneck in 
mucosal transmission in both species. In neither humans 
nor macaques did the numbers of transmitted viruses after 
mucosal exposure correspond to a Poisson distribution of 
independent, low-probability events (5, 31). Diversifica-
tion of SIV and HIV-1 before peak viremia was essentially 
random and without evidence of immune selection; be-
tween peak viremia and 2 wk hence, there was evidence of 
strong CTL selection for escape variants in both macaques 
and humans (Fig. S2) (5, 30, 35, 44, 45). In acute SIV and 
HIV-1 infection, interlineage recombination was common 
(5). Further studies are needed to elucidate the precise na-
ture of the bottleneck to mucosal transmission of SIV and 
HIV-1 and how it compares in rectal versus vaginal trans-
mission. It will also be important to determine if the iden-
tification and enumeration of transmitted/founder viruses 
in humans or macaques can augment in a meaningful way 
the analysis of vaccine-mediated protection or enhance-
ment of infection. Finally, we suggest that the analysis of 
full-length transmitted/founder viruses and their progeny 
in the SIV-macaque infection model can provide a uniquely 
informative view of the composite selection pressures shap-
ing virus evolution beginning at or near the moment of 
transmission and extending to setpoint viremia, as shown 
recently for HIV-1 (30).
MATERIALS AND METHODS
Study animals. Frozen (70°C) plasma specimens collected from 18 adult 
rhesus macaques (Macaca mulatta) as part of a previous study of low-dose 
intrarectal  SIV  inoculation  (41)  were  analyzed.  The  SIVmac251  and 
SIVsmE660 inoculum stocks and the inoculation procedures were previ-
ously described in detail (41). All animals were maintained in an Association 
for Assessment and Accreditation of Laboratory Animal Care–accredited 
institution and with the approval of the Animal Care and Use Committees 
of the National Institutes of Health and Harvard Medical School (41).
Viral RNA extraction and cDNA synthesis. From each plasma speci-
men, 20,000 viral RNA copies were extracted using the QIAamp Viral 
RNA Mini kit (QIAGEN). RNA was eluted and immediately subjected to 
cDNA synthesis. Reverse transcription of RNA to single-stranded cDNA 
was performed using SuperScript III reverse transcription according to man-
ufacturer’s recommendations (Invitrogen). In brief, each cDNA reaction in-
cluded 1× RT buffer, 0.5 mM of each deoxynucleoside triphosphate, 5 mM 
dithiothreitol, 2 U/ml RNaseOUT (RNase inhibitor), 10 U/ml of Super-
Script III reverse transcription, and 0.25 mM antisense primer SIVsm/
macEnvR1 5-TGTAATAAATCCCTTCCAGTCCCCCC-3 (nt 9454–9479 
in SIVmac239). The mixture was incubated at 50°C for 60 min, followed by 
an increase in temperature to 55°C for an additional 60 min. The reaction 
was then heat-inactivated at 70°C for 15 min and treated with 2 U of RNase 
H at 37°C for 20 min. The newly synthesized cDNA was used immediately 
or frozen at 80°C.
SGA. cDNA was serially diluted and distributed among wells of replicate 
96-well plates so as to identify a dilution where PCR-positive wells consti-
tuted <30% of the total number of reactions, as previously described (5, 35). 
At this dilution, most wells contain amplicons derived from a single cDNA 
molecule. This was confirmed in every positive well by direct sequencing of 
the amplicon and inspection of the sequence for mixed bases (double peaks), 
which would be indicative of priming from more than one original template 
or the introduction of PCR error in early cycles. Any sequence with mixed 
bases was excluded from further analysis. PCR amplification was performed 
in the presence of 1× High Fidelity Platinum PCR buffer, 2 mM MgSO4, 
0.2 mM of each deoxynucleoside triphosphate, 0.2 µM of each primer, and 
0.025 U/µl Platinum Taq High Fidelity polymerase in a 20-µl reaction (Invi-
trogen). First round PCR primers included sense primer SIVsm/macEnvF1 
5-CCTCCCCCTCCAGGACTAGC-3  (nt  6127–6146  in  SIVmac239) 
and  antisense  primer  SIVsm/macEnvR1  5-TGTAATAAATCCCTTC-
CAGTCCCCCC-3 (nt 9454–9479 in SIVmac239), which generated an 
3.3-kb amplicon. PCR was performed in MicroAmp 96-well reaction 
plates (Applied Biosystems) with the following PCR parameters: 1 cycle 
of 94°C for 2 min, 35 cycles of a denaturing step of 94°C for 15 s, an an-
nealing step of 55°C for 30 s, and an extension step of 68°C for 4 min, fol-
lowed by a final extension of 68°C for 10 min. Next, 2 µl from first-round 
PCR product was added to a second-round PCR reaction that included the 
sense  primer  SIVsmEnvF2  5-TATGATAGACATGGAGACACCCTTG-
AAGGAGC-3 (nt 6292–6323 in SIVmac239) or SIVmacEnvF2 5-TAT-
AATAGACATGGAGACACCCTTGAGGGAGC-3  (nt  6292–6323  in 
Mac239)  and  antisense  primer  SIVsmEnvR2  5-ATGAGACATRTC-
TATTGCCAATTTGTA-3 (nt 9413–9439 in SIVmac239). The second-
round PCR reaction was performed under the same conditions used for 
first-round PCR, but with a total of 45 cycles. Amplicons were inspected 
on precast 1% agarose E-gels 96 (Invitrogen). All PCR procedures were 
performed under PCR clean room conditions using procedural safeguards 
against sample contamination, including prealiquoting of all reagents, use of 
dedicated equipment, and physical separation of sample processing from pre- 
and post-PCR amplification steps.
DNA sequencing. Env gene amplicons were directly sequenced by cycle-
sequencing using BigDye terminator chemistry and protocols recommended by 
the manufacturer (Applied Biosystems). Sequencing reaction products were ana-
lyzed with an ABI 3730xl genetic analyzer (Applied Biosystems). Both DNA 1132 LOW-DOSE MUCOSAL INFECTION BY SIV | Keele et al.
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